User:W22tgqx0Cm
ニューバランス m1400 The effects of leprosy on men and women
����������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������� ニューバランス m1400 相关的主题文章:
- [1]
- エアジョーダン 11 Bradley said people often chalk up hypothe
- エルメス 財布 Adults' Physically
- ニューバランス 574 but alas one got by him and that was all
- [2]
セリーヌ 店舗 He Doesn't Call Me
He Doesn't Call Me
If you haven't heard from a guy after a great date you may be wondering, should I call him? Perhaps he's lost my number and is not calling me because he doesn't know how to get a hold of me. And this would obviously be a legitimate reason for calling him, right?
Could that really be that he's lost your number? Or was it something that you did or said that made him change his mind about you? You can be going crazy trying to analyze your behavior on a date with this guy. At times a man will tell you straight up, hey I don't think セリーヌ 店舗 it's going to work. Some men will even tell a woman they don't think they are a match even when the women has no interest in seeing him again.
Men are just not wired the way women are, and they don't pick up on subtle intuitive signals a woman is sending. You may be extremely nice and polite on a date and he will perceive it as interest. Yet, you have no romantic interest in him. In which case you really don't care if he likes you エルメス スカーフ or not, if he will call you or not. And deep down you may be hoping that he won't call you again and that he won't pester you anymore.
But sometimes we meet a man and feel that エアジョーダン 6 instant attraction. We may even think he could be the one. We have a エアジョーダン 5 great time chatting and laughing. It is a fantastic date overall and we certainly hope to see this ニューバランス man again very soon. In fact, we sometimes hope to hear from this man the same night.
And the waiting period after the first date may オークリー be the most nerve wrecking time in the relationship. It is when the uncertainty is the highest.
But what if he doesn't call after a date that セリーヌ 財布 seemed to エアジョーダン go so well? Should I call him just to check in with him? Should I call エルメス 時計 him just to remind that I still exist? Should I call him just to make sure he has not lost my number?
Is it better to call him first or to wait for him to call? And what is an appropriate amount of time to wait before calling a man?
Generally men will call women they like within a threeday period after the first date. They have プラダ this threeday rule that I am sure you know about.
But what if three days have passed and you still haven't heard from him? That's when a lot of women get anxious and start wondering, should I call him myself?
Why do men stop calling after a great date? And why even more mysterious men disappear after two or three dates, and even after dating for weeks and months? Find your answers at He Stopped Calling
相关的主题文章:
- [3]
- [4]
- バーバリー コート Mickelson's tears show Tiger wha
- バーバリー コート Crop of new athletes practise wi
- ニューバランス attributes this to a consumer 'flight to qual
エアジョーダン 6 Men's Fashion Photos
Men's Fashion Photos
Fashion Icons Photos
Who are your favorite fashion icons of the 1940's,1950's,1960's, 1970's, 1980's,1990's,and today? エアジョーダン 6 Is it Rita Hayworth, ニューバランス 店舗 Audrey Hepburn, Elizabeth Taylor, Twig.
Men's ニューバランス fashion セリーヌ ラゲージ includes an intricate design on a necktie, a バーバリー 財布 structured sports バーバリー 店舗 coat, a brightly colored polo shirt, a tailored バーバリー 時計 pant, and much more. Men's fashi.
Women's Fashion Photos
Women's fashion can create some of the most beautiful artwork. The couture gowns, gorgeous colors, エアジョーダン 11 and intricate accessories all create breathtaking art. Sho.
Vintage Fashion Photos
Vintage fashion is always popular トリーバーチ 公式 because it brings beauty エルメス to the forefront of the fashion industry. Vintage fashion makes all things old new again. A great .
Shoes Photos
Shoes create some of the most beautiful artwork in the world. The intricate patterns, rich colors, and exquisite attention to details make the costumes b.
相关的主题文章:
- バーバリー コート Women unhappier than men in later life
- トリーバーチ バッグ A touch of makeup
- オークリー アウトレット Michael Morpurgo Month at Sacred Heart Reading Club
- トリーバーチ サンダル ALICE is not very much empha
- コンバース ハイカット Incontinence Pads And Liners
ゴローズ 通販 deprivation therapy in men with metastatic pro
deprivation therapy in men with metastatic prostate cancer
Androgendeprivation therapy in men with metastatic prostate cancer: less ゴローズ 通販 may not necessarily be more
Mark Ng Tang Fui1,2 and Mathis Grossmann1,2In a pivotal phase 3 randomized controlled trial, Hussain et al. tested the hypothesis that, with respect to survival, intermittent androgen deprivation therapy (ADT) is noninferior to continuous in men with newly diagnosed metastatic prostate cancer. While the trial findings were statistically inconclusive, the study suggests, but does not prove, that intermittent may do more harm than good, although findings are not definitive. While outcomes of ongoing trials are awaited, the trial by Hussain et al., in conjunction with an earlier trial in men with nonmetastatic prostate cancer by Crook et al., does provide important new guidance regarding the choice of ADT in men with androgensensitive prostate cancer.
ADT is one of the most effective palliative therapies for patients with metastatic prostate cancer, but not without drawbacks. While not as toxic as chemotherapy, ADT carries a significant risk of morbidity, including sexual dysfunction, fatigue, anemia, accelerated bone loss and fractures, sarcopenia, increased risk of diabetes, and possibly, of cardiovascular events.1,2 In addition, despite an initial response rate of more than 90 most patients develop resistance to ADT, resulting in a median survival of 2.5 years. Preclinical data suggest that continuous use of ADT may accelerate the emergence of resistance to this therapy, and that reexposure of prostate cancer stem cells to androgens can reinduce differentiation and increase their apoptotic potential.3 These ADTassociated shortcomings, in addition to treatment expense, have spurred the development of strategies to minimize the exposure to ADT, including the use of intermittent ADT. While several smaller randomized controlled clinical trials have compared the use of intermittent with continuous ADT, no definitive information is available for patients with metastatic prostate cancer. To fill this evidence gap, a large multinational randomized controlled trial led by Hussain et al.4 was designed in 1993, and outcomes have been published recently in the New England Journal of Medicine. The primary finding from the study was inconclusive, that is, intermittent ADT was not proven to be トリーバーチ サンダル as good as continuous ADT, and there was instead a trend to inferiority. While intermittent ADT was associated with better erectile function and mental health, this benefit did not persist beyond 3 months. Due to the inconclusive finding of this noninferiority trial its findings may be difficult to interpret and apply to clinical practice. Therefore, コンバース we explore this trial in more detail.
The study by Hussain et al.4 enrolled 3040 men from the Unite States, Canada and UK who had newly diagnosed prostate cancer with lymph node, visceral or bone metastases and a prostatespecific antigen (PSA) ng ml Men received a 7month induction course with a luteinizing hormone releasing hormone agonist and antiandrogen (goserelin and bicalutamide, or equivalent) to select androgendependent disease, defined by a PSA ng ml at induction end. One thousand five hundred and thirtyfive men fulfilled this criterion and were then randomized but not blinded to intermittent or continuous ADT, stratified by performance status, prior hormone therapy and extent of disease. Men assigned to continuous therapy continued, whereas men assigned to intermittent therapy discontinued ADT at completion of the 7month induction course. The thresholds for recommencement of ADT in トリーバーチ バッグ the intermittent group were: a rise of PSA to baseline or ng ml or investigator discretion (PSA ng ml or symptomatic disease).
Median age of the randomized population was 70, pretreatment PSA 42 ng ml 96 had an Eastern Cooperative Oncology Group performance status of 0 and 50 had extensive (vs. 50 minimal) disease, and onethird of men had bone pain at the beginning of the induction period, with no difference in men assigned to intermittent (n and continuous (n ADT. Median followup was 9.8 years.
Median duration of protocol therapy トリーバーチ 財布 after randomisation was only 17 months in the continuous group and 19 months in the intermittent group. Those in the intermittent group received ADT for a median 47 of time, and at 15 months, 78 of men in the intermittent group had resumed ADT. Median survival was 5.8 years in the continuous group and 5.1 years in the intermittent group, and 73 to 80 of deaths were related to prostate cancer. The hazard ratio for death was 1.10, representing a 10 increased risk of death with the use of intermittent ADT, with a 90 confidence interval of 0.99 Because the upper limit of the 90 confidence interval exceeded the predefined threshold of 1.20, the hypothesis that intermittent ADT was not inferior to continuous therapy could not be rejected, as the statistical analysis did not rule out the possibility that intermittent therapy was associated with a shorter survival. Since the lower limit of the confidence interval (0.99) crossed unity, intermittent ADT was not, in strict statistical terms, inferior to continuous therapy. However, since nearly the entire confidence interval favoured continuous therapy, there remains the concern that intermittent therapy may compromise survival. Subgroup analysis according to disease extent, PSA and performance status, although limited by small numbers, showed no significant differences in survival. Data on quality of life were available from 1162 men; at 3 months, men assigned to ADT reported less impotence and better quality of life, but these differences did not persist beyond 3 months. However, patients were not blinded ゴローズ 財布 and an emotional response to receiving a treatment break cannot be ruled out. The study was not powered to detect between group difference in highgrade adverse events, with 11 cardiovascular and 2 musculoskeletal events reported in the intermittent, and 15 and 3 in the continuous group.
In summary, because the confidence interval limits crossed both unity and the prespecified delta, the findings by Hussain et al.4 were statistically inconclusive. Thus, the results do not imply that intermittent therapy is inferior; rather, the possibility that intermittent therapy is inferior cannot be discounted. Conversely, the trial has not shown that continuous therapy is superior. Interestingly, in the subgroup analysis, it appeared that predominantly the men with minimal (as opposed to extensive) disease benefitted from continuous therapy, although this finding requires confirmation.
This trial may have been inconclusive for a number of reasons. Firstly, the median survival in both groups (5.1 years) was longer than the predicted (3.5 years) survival used for statistical modelling, and hence, statistical power diminished. In addition, followup may have been to short, with survival curves separating only after 4 years, and the PSA trigger level for therapy resumption in the intermittent ADT group may have been too conservative. Unfortunately, serum testosterone levels were not measured during the trial. Given that testosterone recovery in the offtreatment period is variable, and given that a rise in testosterone would be predicted not only to correlate with improved quality of life measures but also with resensitization of prostate cancer cells to subsequent ADT therapy, analysis by testosterone levels would have been informative. Strengths of the trial include the large number of diseasespecific events, because only patients with metastatic disease, preselected for androgendependent disease were selected.
The trial does not necessarily contradict the results of another recent pivotal phase 3 randomized controlled trial by Crook et al.5 that reported that intermittent ADT was not inferior to continuous ADT with respect to survival. This trial recruited men without evidence of metastatic disease, and patients assigned to intermittent ADT were on therapy only 27 of the time. As expected with earlier stage prostate cancer, median survival was longer (9 years), and prostate cancerspecific mortality (14.2 lower in this trial5 compared to the randomized controlled trial in men with metastatic prostate cancer by Hussain et al.4 While the trial by Crook et al.5 showed noninferiority for overall survival, intermittent therapy was associated with a nonsignificant increase (9 of prostate cancerspecific mortality, with a trend towards reduced overall survival in those with a Gleason score of 8 Because of the relatively low number of prostate cancerrelated deaths, the trial may have been underpowered to show inferiority of intermittent therapy. Interestingly, this was offset by an 8 increase of nonprostate cancer deaths in the continuous ADT group, and, although causality was not proven, it is tempting to speculate that this increase was related to ADTmediated toxicities. In addition, although testosterone recovery to baseline in the offtreatment period occurred in only 35 intermittent ADT was associated with improvements in measures of quality of life, such as better sexual and physical function and less fatigue,5 although the clinical meaningfulness of such statistical improvements is more difficult to delineate. Similar to the trial by Hussain et al.,4 the trial by Crook et al.5 was not powered to detect between group differences in serious ADTassociated adverse events between groups such as minimal trauma fractures or cardiovascular events.
So where do the results of these trial leave us? Collectively, these two pivotal trials4,5 do not support the hypothesis from preclinical data3 that intermittent ADT delays the emergence of castrate resistance disease, but they do inform about patient characteristics predicting suitability for either continuous or intermittent ADT. Clearly, treatment needs to be individualized for a men with prostate cancer, based on potential benefits, and risks with intermittent versus continuous ADT, and the patient should be, where appropriate, involved in decision making.6 Evidence, reviewed elsewhere, suggests that toxicities of ADT are more significant in men with underlying comorbidities, such as cardiometabolic disease and reduced bone mass.1 Conversely, men at higher risk of prostate cancerspecific death are more likely to derive benefit from ADT and less likely to succumb to competing causes of mortality that may be accelerated by ADT. In addition, men will be individually different in their tolerance of ADTassociated decrements in quality of life, such as hot flushes, fatigue and sexual dysfunction. Based on the trial by Crook et al.,5 intermittent ADT therapy should セリーヌ バッグ be considered for most men with nonmetastatic disease, especially in older men with a Gleason score of 7 or less, associated comorbidities, poor tolerance to ADT and slow PSA rises in the offtreatment period. However, based on the results by Hussain et al.,4 intermittent ADT should be used with caution in men with metastatic disease. Men with metastatic disease would be expected to derive less benefit from intermittent ADT because of shorter offtreatment time with less potential for testosterone recovery, and reduced life expectancy. Importantly, if ADT is commenced, patients should be monitored and treated for ADTassociated comorbidities according to evidencebased guidelines7 to minimize the risk of ADTassociated adverse events. Indeed, a recent prospective study has demonstrated that implementation of such guidelines can mitigate ADTassociated cardiovascular risk and bone loss.8
Top of pageReferences
Grossmann M, Zajac JD. Management of side effects of androgen deprivation therapy. Endocrinol Metab Clin North Am 2011; 40: 655 Article PubMed Grossmann M, Zajac JD. Hematological changes during androgen deprivation therapy. Asian J Androl 2012; 14: 187 Article PubMed Akakura K, Bruchovsky N, Goldenberg SL, Rennie PS, Buckley AR et al. Effects of intermittent androgen suppression on androgendependent tumors. Apoptosis and serum prostatespecific antigen. Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med 2013; 368: 1314 Article PubMed CAS Crook JM, O'Callaghan CJ, Duncan G, Dearnaley DP, Higano CS et al. Intermittent androgen suppression for rising PSA level after radiotherapy. N Engl J Med 2012; 367: 895 Article PubMed CAS Grossmann M, Zajac JD. Androgen deprivation therapy in men with prostate cancer: how should the side effects be monitored and treated? Clin Endocrinol (Oxf) 2011; 74: 289 プラダ バッグ Article PubMed Grossmann M, Hamilton EJ, Gilfillan C, Bolton D, Joon DL et al. Bone and metabolic health in patients with nonmetastatic prostate cancer who are receiving オークリー メガネ androgen deprivation therapy. Med オークリー 激安 J Aust 2011; 194: 301 PubMed Cheung AS, Pattison D, Bretherton I, Hoermann R, Lim Joon D et al. Cardiovascular risk and bone loss in men undergoing androgen deprivation therapy for nonmetastatic prostate cancer: implementation of standardised management guidelines. Andrology 2013 (in press).
相关的主题文章:
- バーバリー 財布 A Collection Of Quickly Expanding
- ゴローズ 通販 L'Olympique Jeux vid
- エルメス 財布 Meeting People On Craigslist
- ニューバランス Cougar Dating Tips Why Attractive M
- エルメス 時計 Men before fatal fall from moving bu
トリーバーチ 店舗 Women Men's Camo Hunting Jackets for Less
���������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������� トリーバーチ 店舗 相关的主题文章: